[{"data":1,"prerenderedAt":135},["ShallowReactive",2],{"content-query-1dS9MHrbYG":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"date":10,"cover":11,"type":12,"body":13,"_type":129,"_id":130,"_source":131,"_file":132,"_stem":133,"_extension":134},"/news/zh/3109","zh",false,"","基于昇思MindSpore打造抗体设计模型“天工”，引领生物医药行业创新加速","抗体类药物已被广泛批准用于治疗多种疾病，具有巨大的社会价值，尤其在病毒引起的传染病等方面发挥着重要作用。","2024-05-14","https://obs-mindspore-file.obs.cn-north-4.myhuaweicloud.com/file/2024/05/17/e43ddb9f45894f6c993cbb0cdafd9442.png","news",{"type":14,"children":15,"toc":126},"root",[16,24,30,35,44,49,57,62,69,77,82,90,95,103,108,116,121],{"type":17,"tag":18,"props":19,"children":21},"element","h1",{"id":20},"基于昇思mindspore打造抗体设计模型天工引领生物医药行业创新加速",[22],{"type":23,"value":8},"text",{"type":17,"tag":25,"props":26,"children":27},"p",{},[28],{"type":23,"value":29},"抗体类药物已被广泛批准用于治疗多种疾病，具有巨大的社会价值，尤其在病毒引起的传染病等方面发挥着重要作用。抗体药物市场空间快速发展，然而，传统的抗体设计方法效率低下、成本高昂，难以满足日益增长的临床需求。",{"type":17,"tag":25,"props":31,"children":32},{},[33],{"type":23,"value":34},"针对这些需求与挑战，昌平实验室联合昇思MindSpore打造的“天工”抗体设计模型应运而生。它是一种能够与实验进行交互、具备生物先验知识的生成式AI，能够实现对非人源有效抗体的人源化，从而降低抗体实验研发成本。此外，它还能进一步优化具有功效的抗体的可成药性、降低生产成本，最终实现对可成药抗体的高效增值。它将为抗体药物的研发带来革命性的变革。",{"type":17,"tag":25,"props":36,"children":37},{},[38],{"type":17,"tag":39,"props":40,"children":41},"strong",{},[42],{"type":23,"value":43},"“天工”模型：引领抗体设计新潮流",{"type":17,"tag":25,"props":45,"children":46},{},[47],{"type":23,"value":48},"“天工”抗体设计模型是基于昇思MindSpore打造的一款创新工具，能够实现抗体功能设计、序列嫁接和活性预测等多种任务。天工模型设计效率相比传统抗体设计方法提升一个数量级以上，基于天工模型嫁接改造得到的人源抗体，经协和医学院团队验证抗体表达量提升约5至10倍，有望将抗体生产成本降低2倍以上。",{"type":17,"tag":25,"props":50,"children":51},{},[52],{"type":17,"tag":53,"props":54,"children":56},"img",{"alt":7,"src":55},"https://obs-mindspore-file.obs.cn-north-4.myhuaweicloud.com/file/2024/05/17/60db1d7447f34eaa891f019eb14482e0.png",[],{"type":17,"tag":25,"props":58,"children":59},{},[60],{"type":23,"value":61},"“天工”抗体设计模型是业界多领域交叉融合的杰出成果。依托昇腾硬件与昇思MindSpore AI框架的基础软硬件能力， “天工”模型实现高效训练和推理。昌平实验室则为该模型注入了抗体设计领域的生物先验知识，使其能够同时支持高精度的功能设计和嫁接设计。协和医学院以其丰富的临床经验，迅速对新设计的抗体进行实验验证，并将湿实验结果反馈至模型，形成了干湿实验的闭环，为“天工”模型的完善和应用提供了强有力的支持。",{"type":17,"tag":25,"props":63,"children":64},{},[65],{"type":17,"tag":53,"props":66,"children":68},{"alt":7,"src":67},"https://obs-mindspore-file.obs.cn-north-4.myhuaweicloud.com/file/2024/05/17/15fe87e1381b4ab49b844f9a46e9edb0.png",[],{"type":17,"tag":25,"props":70,"children":71},{},[72],{"type":17,"tag":39,"props":73,"children":74},{},[75],{"type":23,"value":76},"软件协同：高效内存复用，模型性能提升",{"type":17,"tag":25,"props":78,"children":79},{},[80],{"type":23,"value":81},"昇思MindSpore结合框架高效的内存复用能力，使用了重计算技术对模型进行优化。该技术网络正向执行是释放激活层的计算结果，在模型反向计算时重新计算正向激活层的结果，有效降低峰值内存，最终将训练内存减少了10倍。lazy inline编译优化技术，能标记循环体中频繁调用的子图，推迟inline处理至编译的最后阶段，大幅度缩短了编译时间，将“天工”模型的编译性能提升了5倍以上。",{"type":17,"tag":25,"props":83,"children":84},{},[85],{"type":17,"tag":39,"props":86,"children":87},{},[88],{"type":23,"value":89},"高效设计：降低研发成本，加速临床应用",{"type":17,"tag":25,"props":91,"children":92},{},[93],{"type":23,"value":94},"传统抗体研发投入成本高，导致许多抗体开发商长期亏损，而人源抗体的湿实验成本也相对昂贵。“天工”模型通过多段功能区域的联合分布改造生成抗体序列，能够高效筛选出具有优良活性的抗体候选。经过实验验证，经过“天工”模型嫁接改造的抗体相较于原始抗体，表达产率提升了约5~10倍。这一显著提升的表达产率为生产环节带来了巨大的效益。表达产率的提升意味着在相同的生产周期内，可以获得更多的抗体产品，从而降低了单位抗体的生产成本。",{"type":17,"tag":25,"props":96,"children":97},{},[98],{"type":17,"tag":39,"props":99,"children":100},{},[101],{"type":23,"value":102},"智能预测：提升抗体活性，优化治疗效果",{"type":17,"tag":25,"props":104,"children":105},{},[106],{"type":23,"value":107},"“天工”模型还具备强大的活性预测能力，能够准确预测抗体的生物活性，为优化抗体结构、提升治疗效果提供了有力依据。通过智能预测，研究人员可以更加精准地筛选出具有优良活性的抗体，提高药物研发的成功率。针对一个具有潜在癌症治疗功效的鼠源抗体选择作为人源化目标，通过“天工”模型进行嫁接后得到的抗体序列，相比于原始序列在人源性得分上达到了70%以上的提升，人源性分数表示人源化后的抗体与人类抗体序列的一致性程度，通常较高的人源性分数表示临床免疫原性更低、稳定性更高。",{"type":17,"tag":25,"props":109,"children":110},{},[111],{"type":17,"tag":39,"props":112,"children":113},{},[114],{"type":23,"value":115},"推动生物医药产业繁荣发展",{"type":17,"tag":25,"props":117,"children":118},{},[119],{"type":23,"value":120},"“天工”模型不仅探索了AI在面向临床的抗体和制药领域的巨大潜力，而且在合作伙伴方面取得了显著的优势互补。通过与昇思MindSpore开源社区、昌平实验室以及协和医学院的合作，实现了多方面的协同创新，推动了抗体设计领域的技术革新。该模型在高通量方面的突破使得抗体设计的速度得以显著提升，能够更加迅速、精准地应对临床需求。与此同时，通过人源化嫁接使得抗体生成成本得到有效控制。",{"type":17,"tag":25,"props":122,"children":123},{},[124],{"type":23,"value":125},"在合作伙伴的共同努力下，“天工”模型的成功应用不仅推动了科学研究的前沿，也为抗体和制药领域的未来发展描绘了更加光明的前景。这种跨界合作的模式为不同领域的专业知识提供了一个有机结合的平台，为推动医学科技的创新贡献了重要力量。",{"title":7,"searchDepth":127,"depth":127,"links":128},4,[],"markdown","content:news:zh:3109.md","content","news/zh/3109.md","news/zh/3109","md",1776506080357]